30
Apr, 2020
Invasive ventilation in children during COVID-19 pandemic
30 April 2020
A webinar by ESPNIC
COVID-19 Media
29
Apr, 2020
Fecal-oral transmission of Sars-Cov-2 in children: is it time to change our approach?
Pediatr Infect Dis J, April 2020
28
Apr, 2020
Family-centered care in the PICU during the COVID-19 pandemic
28 April 2020
A webinar by ESPNIC
28
Apr, 2020
Clinical characteristics and risk assessment of newborns born to mothers with COVID-19
J Clin Virol, April 2020
28
Apr, 2020
28
Apr, 2020
28
Apr, 2020
A comparison of five paediatric dosing guidelines for antibiotics
Authors: Mathur S, Jackson C, Urus H, Ziarko I, Goodbun M, Hsia Y, Ellis S, Sharland M. Published in: Bulletin of the World Health Organization, April 2020 Objective To compare dosing guidance in the paediatric formularies of high-income countries and emerging economies for 32 commonly prescribed antibiotics on the World Health Organization’s (WHO’s) 2017 Model List of Essential Medicines for Children. Methods We identified paediatric antibiotic guidelines that were either widely used internationally or originated in countries in which antibiotic use has increased markedly in recent years (i.e. Brazil, China, […]
27
Apr, 2020
The bat, the pangolin and the city: a tale of COVID-19
27 April 2020
An overview of COVID-19 pandemic from a wildlife biology perspective
26
Apr, 2020
Interim pharmacokinetic analysis of a multi-centre randomised open label phase IIb study in neonates to validate the meta-analysis population pharmacokinetic model used to simulate an optimised dosing regimen in neonates and infants aged < 90 days: the NeoVanc trial
Authors: L. Hill, E. Jacqz-Aigrain, V. Elie, W. Zhao, M. Clements, M. Turner, I. Lutsar, P. Heath, E. Roilides, S. Walker, M. Sharland Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020 Background: Vancomycin remains one of the most widely prescribed antibiotics for Gram-positive neonatal late onset sepsis (LOS), however, a consensus on optimal vancomycin dosing and duration is lacking. Robust neonatal clinical pharmacokinetic (PK) data comparing different vancomycin dosing regimens remain sparse. NeoVanc (NCT02790996) is a European, randomised controlled, non-inferiority trial comparing an optimised […]
26
Apr, 2020
An optimised dosing regimen vs. a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in infants less than 90 days: the NeoVanc trial
Authors: L. Hill, M. Clements, M. Turner, I. Lutsar, E. Jacqz-Aigrain, P. Heath, E. Roilides, S. Walker, M. Sharland Published in: 30th European Congress on Clinical Microbiology and Infectious Diseases (ECCMID), April 2020 Background: Vancomycin remains one of the most widely prescribed antibiotics for Gram-positive neonatal late onset sep- sis (LOS). Robust neonatal clinical outcome data comparing different vancomycin dosing regimens is lacking. NeoVanc (NCT02790996) is a European, multicentre, phase IIb, randomised controlled, non-inferiority trial comparing an optimised and standard vancomycin regimen in infants aged ≤90 days with known/suspected Gram-positive […]
